Airway basal cells show a dedifferentiated KRT17<sup>high</sup>Phenotype and promote fibrosis in idiopathic pulmonary fibrosis.

Jaeger, Benedikt; Schupp, Jonas Christian; Plappert, Linda; Terwolbeck, Oliver; Artysh, Nataliia; Kayser, Gian; Engelhard, Peggy; Adams, Taylor Sterling et al. · Nat Commun · 2022

basic_science · Level V

Where this comes from

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal disease with limited treatment options. In this study, we focus on the properties of airway basal cells (ABC) obtained from patients with IPF (IPF-ABC). Single cell RNA sequencing (scRNAseq) of bronchial brushes revealed extensive reprogramming of IPF-ABC towards a KRT17<sup>high</sup> PTEN<sup>low</sup> dedifferentiated cell type. In the 3D organoid model, compared to ABC obtained from healthy volunteers, IPF-ABC give rise to more bronchospheres, de novo bronchial structures resembling lung developmental processes, induce fibroblast proliferation and extracellular matrix deposition in co-culture. Intratracheal application of IPF-ABC into minimally injured lungs of Rag2<sup>-/-</sup> or NRG mice causes severe fibrosis, remodeling of the alveolar compartment, and formation of honeycomb cyst-like structures. Connectivity MAP analysis of scRNAseq of bronchial brushings suggested that gene expression changes in IPF-ABC can be reversed by SRC inhibition. After demonstrating enhanced SRC expression and activity in these cells, and in IPF lungs, we tested the effects of saracatinib, a potent SRC inhibitor previously studied in humans. We demonstrate that saracatinib modified in-vitro and in-vivo the profibrotic changes observed in our 3D culture system and novel mouse xenograft model.

Medical subject headings